- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- February 2026
- 250 Pages
Global
From €4127EUR$4,490USD£3,518GBP
- Report
- October 2026
- 275 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- October 2026
- 269 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- October 2026
- 213 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- October 2026
- 423 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- October 2026
- 252 Pages
Global
From €5378EUR$5,850USD£4,583GBP
- Report
- March 2026
- 150 Pages
Global
From €3447EUR$3,750USD£2,938GBP
- Report
- August 2026
- 120 Pages
Global
From €4366EUR$4,750USD£3,721GBP
- Report
- July 2026
- 110 Pages
Global
From €4366EUR$4,750USD£3,721GBP
- Report
- July 2026
- 135 Pages
Global
From €4366EUR$4,750USD£3,721GBP
- Report
- August 2026
- 178 Pages
Global
From €3631EUR$3,950USD£3,095GBP
- Report
- August 2026
- 176 Pages
Global
From €3631EUR$3,950USD£3,095GBP
- Report
- August 2026
- 160 Pages
Global
From €3052EUR$3,320USD£2,601GBP
€3815EUR$4,150USD£3,251GBP
- Report
- August 2026
- 160 Pages
Global
From €3052EUR$3,320USD£2,601GBP
€3815EUR$4,150USD£3,251GBP
- Report
- January 2026
- 160 Pages
Global
From €2905EUR$3,160USD£2,476GBP
€3631EUR$3,950USD£3,095GBP
- Report
- November 2025
- 160 Pages
Global
From €2905EUR$3,160USD£2,476GBP
€3631EUR$3,950USD£3,095GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more